Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2025 16:01 ET | Source: Pasithea

Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

In new data, MEK inhibitor PAS-004 shows monotherapy partial response, favorable PK and safety profile, supporting best-in-class potential for NF1-PN.
December 09, 2024 19:30 ET | Source: Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma

IGI Presents 1st Clinical Data from Ph 1 Study of Trispecific Antibody, ISB 2001, Showing High ORR & Favorable Safety Profile in Heavily Treated RRMM Pts.
May 11, 2023 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

- Key Catalysts ahead with multiple Value Generating Readouts -- Expects to Report Phase 1/2 Data Releases with Oral Fadraciclib -- Advancing single-agent Efficacy with Differentiated Oral Plogosertib...